公开(公告)号：US20210130451A1

公开(公告)日：2021-05-06

申请号：US17144685

申请日：2021-01-08

Applicant: MORPHOSYS AG

Inventor： Stefan HARTLE ,  Stephane LECLAIR ,  Amgad SHEBL ,  Stefan STEIDL ,  Bodo BROCKS ,  Daniela Della DUCATA ,  Kai ROSPORT

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/395

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

公开(公告)号：US20220213190A1

公开(公告)日：2022-07-07

申请号：US17700809

申请日：2022-03-22

Applicant: MorphoSys AG

Inventor： Patrick GARIDEL ,  Andreas LANGER ,  Martin HESSLING ,  Daniel WEINFURTNER ,  Bodo BROCKS

IPC: C07K16/28 ,  A61K47/54 ,  A61K9/19 ,  A61K31/715 ,  A61K47/36

Abstract: The present disclosure describes a pharmaceutical formulation of an anti-CD19 antibody.

公开(公告)号：US20240417455A1

公开(公告)日：2024-12-19

申请号：US18817360

申请日：2024-08-28

Applicant: MORPHOSYS AG

Inventor： Stefan HARTLE ,  Stephane LECLAIR ,  Amgad SHEBL ,  Stefan STEIDL ,  Bodo BROCKS ,  Daniela Della DUCATA ,  Kai ROSPORT

IPC: C07K16/24 ,  A61K31/519 ,  A61K39/00 ,  A61K39/395 ,  C07K16/28

Abstract: The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.

公开(公告)号：US20220110872A1

公开(公告)日：2022-04-14

申请号：US17298156

申请日：2019-12-13

Applicant: MORPHOSYS AG

Inventor： Bodo BROCKS ,  Robert KELLERER

IPC: A61K9/19 ,  C07K16/28

Abstract: The present disclosure relates to formulations of a pharmaceutically active antigen binding protein, such as a monoclonal antibody. In particular, the present disclosure relates to a stable lyophilized pharmaceutical formulation of an anti-CD38 antibody, a reconstituted liquid formulation of such lyophilized formulation, and to methods of making and using such lyophilized and reconstituted formulations.